Suppr超能文献

高级别浆液性卵巢癌患者的病理化疗反应评分:网膜和卵巢残留病灶的预后作用

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease.

作者信息

Santoro Angela, Angelico Giuseppe, Piermattei Alessia, Inzani Frediano, Valente Michele, Arciuolo Damiano, Spadola Saveria, Mulè Antonino, Zorzato Piercarlo, Fagotti Anna, Scambia Giovanni, Zannoni Gian Franco

机构信息

Unità di Gineco-patologia e Patologia Mammaria, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Unità di Ginecologia Oncologica, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

出版信息

Front Oncol. 2019 Aug 19;9:778. doi: 10.3389/fonc.2019.00778. eCollection 2019.

Abstract

The chemotherapy response score (CRS) has emerged as a simple and reproducible histopathological grading system for assessing chemotherapy response in patients affected by ovarian high-grade serous carcinoma. To evaluate the prognostic impact of histological tumor response in ovarian and omental surgical specimens from patients with advanced stage ovarian high-grade serous carcinoma. A cohort of 161 women were identified from the database of Department of Gynecology, "Fondazione Policlinico Universitario Agostino Gemelli IRCCS" of Rome, Italy between January 2014 and December 2017 with a follow-up of 65 months. All the omentum, the ovarian tissue and peritoneal samples, defined as "other sites," were reviewed by gynecological pathologists to assign a CRS of 1-3 to the omentum and ovarian sites and a score of 0-1 to the peritoneal tissue. The Cox proportional hazards regression and the log-rank test were used to assess the survival pattern and the prognostic value of the CRS adjusting for age and stage. The Kaplan-Meier method was applied to estimate the progression free and overall survival. The evaluation of adnexal disease showed significant differences in PFS, both in univariate and in multivariate analyses. On PFS univariate analysis, ovCRS1 vs. ovCRS3: HR, 2.27; 95% CI, 1.37-3.77; = 0.001; ovCRS2 vs. ovCRS3: HR, 1.83; 95% CI, 1.03-3.23; = 0.04, and on PFS multivariate model ovCRS1 vs. ovCRS3; HR, 2.53; 95% CI, 1.5-4.24; = 0.001 and ovCRS2 vs. ovCRS3; HR, 1.90; 95% CI, 1.08-3.37; = 0.03. Regarding the omental residual disease, as expected, CRS showed a significant prognostic value for OS and PFS; in detail the median PFS of patients with CRS1, 2 and 3 was 15, 15, and 22 months, respectively, the median OS was 41 and >50 months, respectively. Moreover, the univariate analysis for OS suggested that in our cohort the "other sites" score of 0 was significantly associated with an improvement in overall survival compared to score 1. We demonstrated for the first time the prognostic significance of adnexal CRS confirming also the prognostic role of omental CRS.

摘要

化疗反应评分(CRS)已成为一种简单且可重复的组织病理学分级系统,用于评估卵巢高级别浆液性癌患者的化疗反应。为了评估晚期卵巢高级别浆液性癌患者卵巢和网膜手术标本中组织学肿瘤反应的预后影响。从意大利罗马“圣心天主教大学综合医院阿戈斯蒂诺·杰梅利IRCCS基金会”妇科数据库中确定了161名女性,随访时间为65个月,时间跨度从2014年1月至2017年12月。妇科病理学家对所有网膜、卵巢组织和腹膜样本(定义为“其他部位”)进行检查,为网膜和卵巢部位分配1 - 3分的CRS,为腹膜组织分配0 - 1分。使用Cox比例风险回归和对数秩检验来评估生存模式以及调整年龄和分期后的CRS预后价值。应用Kaplan - Meier方法估计无进展生存期和总生存期。附件疾病的评估显示,在单因素和多因素分析中,无进展生存期均存在显著差异。在无进展生存期的单因素分析中,卵巢CRS1与卵巢CRS3相比:风险比(HR)为2.27;95%置信区间(CI)为1.37 - 3.77;P值 = 0.001;卵巢CRS2与卵巢CRS3相比:HR为1.83;95% CI为1.03 - 3.23;P值 = 0.04,在无进展生存期多变量模型中,卵巢CRS1与卵巢CRS3相比;HR为2.53;95% CI为1.5 - 4.24;P值 = 0.001,卵巢CRS2与卵巢CRS3相比;HR为1.90;95% CI为1.08 - 3.37;P值 = 0.03。关于网膜残留疾病,正如预期的那样,CRS对总生存期和无进展生存期显示出显著的预后价值;具体而言,CRS为1、2和3的患者的无进展生存期中位数分别为15、15和22个月,总生存期中位数分别为41个月和超过50个月。此外,总生存期的单因素分析表明,在我们的队列中,“其他部位”评分为0与评分为1相比,总生存期显著改善。我们首次证明了附件CRS的预后意义,同时也证实了网膜CRS的预后作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c0/6709655/050496271363/fonc-09-00778-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验